Conference abstract · 26 Sep 2019
Conference abstractPublished 8 Jun 2015
M2SR, a single replication universal flu vaccine
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Influenza (flu) virus causes a respiratory disease resulting in over 200,000 hospitalizations and ~36,000 deaths per year in the US Flu vaccines have remained virtually unchanged for decades. Despite the annual update of the three hemagglutinin (HA) vaccine antigens to match the circulating influenza strain, current vaccine efficacy is estimated to be ~60% across the population as a whole and much less for the elderly. Flu vaccine protection is sub-optimal and substantially lower than for most routinely recommended vaccines. The low efficacy rates are due primarily to the relatively poor immune response provided by both inactivated and live vaccines. There is an urgent need for highly protective flu vaccines that provide broad-spectrum immunity across all segments of the population. FluGen has developed a new vaccine, M2SR (Single Replication) which exploits the best features of both inactivated and live attenuated influenza vaccines. Like the inactivated vaccine, it elicits a strong humoral response against the major neutralizing antigen, the HA. Similar to the live attenuated influenza vaccine, it is administered intra-nasally to mimic a natural infection and induce broad-spectrum immunity including mucosal and cellmediated responses. The novelty of M2SR is that the vaccine virus presents multiple antigen targets to the immune system like a wild-type virus and activates the immune system without production of progeny virus. We have shown that the M2SR vaccine provides broad-spectrum, long-lasting cross-protection against multiple influenza subtypes including H5N1 in mice and ferrets.
Subjects
Infectious DiseasesMicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 6 Dec 2018
Recombinant approach to develop ScFv antibodies and vaccines against viral diseases as Ebola, Flu (AH1N1) and Cancer (Polyomavirus)Antibiotic use in relation with long term morbidities
Conference abstract · 2 Jul 2018
Novel platform (wEB) to study flu virus evolution and predict vaccine efficacy
Conference abstract · 8 Jun 2015
Designing effective flu vaccines against a broad-spectrum of influenza viruses
Conference abstract
Prevalence of the flu vaccination in a working population
More from this journal
The newest in Virology & Mycology.
Perspective · 3 Apr 2025
Biofilm Formation and Drug Resistance in Viral and Fungal Coinfections
Perspective · 3 Apr 2025
Climate Change and the Evolution of Virulent Viral and Fungal Strains
Commentary · 3 Apr 2025
Next Generation Diagnostics for Rapid Detection of Viruses and Fungi
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalVirology & Mycology
- SubjectInfectious Diseases
- SubjectMicrobiology
- BylineArticles whose byline prints “Pamuk Bilsel”

